Previous 10 | Next 10 |
Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...
SAN CARLOS, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following virtual conferences in June: G...
SAN CARLOS, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and perip...
Iovance Biotherapeutics ( IOVA -1.2% ) announces long-term follow-up data from cohort 2 in its Phase 2 C-144-01 study evaluating autologous tumor infiltrating lymphocyte (TIL) therapy lifileucel in metastatic melanoma patients. More news on: Iovance Biotherapeutics, Inc., Healthcare ...
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up 36.4% Overall Response Rate (ORR) Maintained SAN CARLOS, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cel...
Iovance Biotherapeutics (NASDAQ: IOVA ) has priced its public offering of 16,935,484 common shares at $31.00/share, for expected gross proceeds of ~$525M. More news on: Iovance Biotherapeutics, Inc., Healthcare stocks news, , Read more ...
SAN CARLOS, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and periph...
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) fell as much as 15.7% today after the company announced a proposed public offering of common stock. The development-stage biopharma is looking to raise up to $575 million in gross proceeds. Although pricing has yet to be announced, an offering...
Gainers: ARCA biopharma (NASDAQ: ABIO ) +174% . More news on: ARCA biopharma, Inc., Monaker Group, Inc., Triumph Group, Inc., Stocks on the move, , Read more ...
Iovance Biotherapeutics (NASDAQ: IOVA ) announces preliminary data from cohort 4 in its Phase 2 clinical trial evaluating lifileucel (LN-144) in metastatic melanoma patients. More news on: Iovance Biotherapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
8.86%Change Percent:
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and...
2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL recommendation for IOVA on July 29, 2024 02:11AM ET. The previous analyst recommendation was Overweight. IOVA was trading at $9.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-29 05:00:08 ET Joseph Catanzaro from Piper Sandler issued a price target of $10.00 for IOVA on 2024-07-29 02:11:00. The adjusted price target was set to $10.00. At the time of the announcement, IOVA was trading at $9.25. The overall price target consensus is at $...